Study #2020-0158
Diet and Immune Effects Trial: DIET- A randomized double blinded dietary intervention study in patients with metastatic melanoma receiving immunotherapy
MD Anderson Study Status
Not Accepting
Treatment Agent
Description
This is a randomized, double-blind, fully controlled feeding study that will enroll melanoma patients starting standard-of-care ICB in three settings: adjuvant, neoadjuvant, and unresectable. Patients are randomized to the high fiber or healthy control diet. The goal of the study is to establish the effects of dietary intervention on the structure and function of the gut microbiome in patients with melanoma treated with SOC immunotherapies.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Clinical Stage III Cutaneous Melanoma AJCC v8;Clinical Stage IV Cutaneous Melanoma AJCC v8;Metastatic Melanoma;Pathologic Stage III Cutaneous Melanoma AJCC v8;Pathologic Stage IV Cutaneous Melanoma AJCC v8;Unresectable Melanoma;Stage II Melanoma;Uveal Melanoma;Mucosal Melanoma;Unresectable Clear Cell Renal Cell Carcinoma
Study phase:
Phase II
Physician name:
Erez Baruch
Department:
Melanoma Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.